The timing of drug administration for thromboprophylaxis following orthopaedic surgery: Evidence and controversies related to treatment initiation and duration

Current Vascular Pharmacology

Volumn 9, Issue 1, 2011, Pages 11-18

  Papakostidis, Costas ^a   Harwood, Paul J ^b   Karadimas, Efthimios J ^b   Tan, Hiang Boon ^b   Giannoudis, Peter V ^b  

^a G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Orthopaedic surgery; Trauma; Venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HIP ARTHROPLASTY; HIP FRACTURE; HUMAN; KNEE SURGERY; META ANALYSIS (TOPIC); ORTHOPEDIC SURGERY; POSTOPERATIVE CARE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOEMBOLISM;

EID: 78650963072     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111793744698     Document Type: Article

References (66)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 338S-400S.
2. Zimlich RH, Fulbright BM, Friedman RJ. Current status of anticoagulation therapy after total hip and total knee arthroplasty. J Am Acad Orthop Surg 1996; 4: 54-62.
3. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S-175S.
4. Prandoni P, Lensing AWA, Cogo A, et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
5. Dahl OE, Aspelin T, Lyberg T. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coagul Fibrinolysis 1995; 6: 709-17.
6. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement thrombosis and haemostasis. Thromb Haemost 1988; 60: 407-10.
7. Boris L, Hauch O, Jorgensen L, Hansen B, for the Danish Enoxaparin Study Group. Low-molecular weight heparin (enoxaparin) vs. dextran 70: the prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med 1991; 151:1621-4.
8. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop Scand 1991; 62: 33-8.
9. Eriksson BI, Kälebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg Am 1991; 73-A: 484-93.
10. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303: 543-8.
11. Planes A, Vochelle N, Fagola M, Feret J, Bellaud M. Prevention of deep vein thrombosis after total hip replacement: the effect of low molecular-weight heparin with spinal and general anaesthesia. J Bone Joint Surg Br 1991; 73-B: 418-23.
12. Torholm C, Broeng L, Jorgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: a placebo controlled study. J Bone Joint Surg Br 1991; 73-B: 434-8.
13. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992; 111: 110-20.
14. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
15. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin vs. placebo. Lancet 1996; 348: 224-8.
16. Eriksson B, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.
17. Planes A, Samama M, Lensing A, et al. Prevention of deep vein thrombosis after total hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81: 22-5.
18. Wu CL. Regional anaesthesia and anticoagulation. J Clin Anesth 2001; 13: 49-58.
19. Hantler C, Despotis GJ, Shinha R, et al. Guidelines and alternatives for neuraxial anesthesia and venous thromboembolism prophylaxis in major orthopaedic surgery. J Arthroplasty 2004; 19: 1004-16.
20. Hull RD, Raskob GE, Pineo GF, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for pro-phylaxis against deepvein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6.
21. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deepvein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-9.
22. Colwell CW Jr, Spiro TE, Trowbridge AA, et al.; for the Enoxa-parin Clinical Trial Group. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety. J Bone Joint Surg Am 1994; 76-A: 3-14.
23. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995; 155: 366-72.
24. Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997; 79-A: 1365-72.
25. Hull RD, Pineo GF, Francis C, et al.; for the North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs. warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med 2000; 160: 2199-207.
26. Nicolaides AN, Bergqvist D, Hull RD, et al. Prevention of venous thromboembolism: International Consensus Statement. Int Angiol 1997; 16: 3-38.
27. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty. Arch Intern Med 2001; 161: 1952-60.
28. Hamulyák K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA, for the Fraxiparine Oral Anticoagulant Study Group. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemost 1995; 74: 1428-31.
29. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
30. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
31. Turpie AG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux vs. postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-6.
32. Lassen MR, Bauer KA, Eriksson BI, Turpie AG, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux vs. preoperative enoxaparin for prevention of venous thromboembolism in elective hipreplacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
33. Eriksson BI, Bauer KA, Lassen MR, Turpie AG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
34. Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-6.
35. Kalodiki EP, Hoppensteadt DA, Nicolaides AN, et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement: a randomized controlled trial. Int Angiol 1996; 15: 162-8.
36. Planes A. Comparison of antithrombotic efficacy and haemorrhagic side-effects of clivarin vs. enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis 1993; 4(suppl 1): S33-S38.
37. Planes A, Vochelle N, Fagola M, et al. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. Acta Chir Scand Suppl 1990; 556: 108-15.
38. Colwell CW Jr, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop 1995; 321: 215-22.
39. Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K, for the Arar Study Group. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Br J Anaesth 1997; 78: 660-5.
40. Spiro TE, Johnson GJ, Christie MJ, et al, for the Enoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994; 121: 81-9.
41. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate vs. enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
42. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
43. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs. North-American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
44. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban vs. enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
45. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban vs. enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86.
46. Turpie AG, Bauer KA, Davidson B, et al. Comparison of rivaroxaban, an oral direct Factor Xa inhibitor, and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase III study): Proceedings of the 9th EFORT Congress. Nice, May 30, 2008. Abstract F85.
47. Pellegrini VD Jr, Clement D, LushEhmann C, Keller GS, Evarts CM. The John Charnley Award. Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop 1996; 333: 27-40.
48. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001; 83: 336-45.
49. Trowbridge A, Boese CK, Woodruff B, Brindley H Sr, Lowry WE, Spiro TE. Incidence of post hospitalization proximal deep venous thrombosis after total hip arthroplasty: a pilot study. Clin Orthop 1994; 299: 203-8.
50. Turpie AG. Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge. Orthopedics 1995; 18: 15-7.
51. Bergqvist D. Long-term prophylaxis after orthopaedic surgery. Haemostasis 1993; 1: 27-31.
52. Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investi-gating symptomatic outcomes. Arch Intern Med 2002; 162: 1465-71.
53. Robinson KS, Anderson DR, Gross M, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the Post-Arthoplasty Screening Study; a randomized, controlled trial. Ann Intern Med 1997; 127: 439-45.
54. Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin. Arch Intern Med 1998; 158: 873-8.
55. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999; 81: 932-40.
56. Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 2000; 132: 853-61.
57. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-31.
58. Eikelboom JW, Quinlan DJ, Douketis JD: Extended-duration pro-phylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.
59. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135: 858-69.
60. Guyatt G, Schünemann HJ, Cook D, Jaeschke R, Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 179S-87S.
61. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: a costutility analysis. Arch Orthop Trauma Surg 2004; 124: 507-17.
62. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban vs. shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008: 372: 31-9.
63. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban vs. enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet 2009; 373: 1673-80.
64. Callaghan JJ, Dorr LD, Engh GA, et al. American College of Chest Physicians. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians-are they appropriate for orthopaedic surgery? J Arthroplasty 2005; 20: 273-4.
65. Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Selected In-structional Course Lectures. The American Academy of Orthopaedic Surgeons: Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg 2008; 90-A: 2763-80.
66. Conduah A, Lieberman JR. Venous thromboembolic prophylaxis after elective total hip arthroplasty. Clin Orthop 2005; 441: 274-84.